Overview

Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:
0

Participant gender:
All

Summary

This study has been important in establishing synthetic human parathyroid hormone 1-34 (PTH) as a beneficial treatment for hypoparathyroidism, superior to conventional therapy with calcium and calcitriol. Providing synthetic human parathyroid hormone 1-34 (PTH) to patients who are unresponsive to conventional therapy has enabled severe cases of hypoparathyroidism to be managed effectively with the investigational drug, PTH. The primary goals of this study are to (1) provide long-term PTH therapy to patients who do not respond to conventional therapy; (2) understand the long-term effect of therapeutic PTH replacement on kidney function and bone mineral density; (3) study and track linear growth and bone accrual in children with hypoparathyroidism. (4) determine if subjects reach a normal level of peak bone mass and if the timing of this is comparable to normal age-matched healthy controls.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Treatments:

Calcitriol
Calcium
Calcium, Dietary
Hormones
Parathyroid Hormone
Vitamin D
Vitamins

Criteria

- INCLUSION CRITERIA:

This study will include patients (ages 17-69) with biochemically confirmed
hypoparathyroidism.

EXCLUSION CRITERIA

Women who are pregnant will be excluded.